PNH Registry

Trial Overview

Primary:
•The PNH Registry will collect data to evaluate safety data specific to the use of Soliris
•The PNH Registry will collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris and non-Soliris treated patients

Secondary:
•Facilitates sub-studies in Soliris treated PNH patients that were requested by regulatory authorities such as: Immunogenicity evaluation [Human Anti-Human Antibodies (HAHA) sub-study] and Thromboprophylaxis withdrawal study (Parasol study)
•Raising PNH awareness in the medical community and subject/potential subject population.

Inclusion criteria

•Patients that are receiving Soliris for any indication,OR
•PNH patients that are not on Soliris treatment

Principal Investigator

Dr Hillmen

Tel: 01132068513

E-mail: peter.hillmen@nhs.net

PNH CNS

Louise Arnold

Tel: 01132068273

E-mail: louise.arnold@leedsth.nhs.uk

Other trials currently active for Paroxysmal Nocturnal Hemoglobinuria

warning icon

Sorry, there are currently no other active trials

However, these pages are regularly updated with new trials so please check back again soon when new trials may be available.

Tags